Trial reportPloS one2026
Effect of esketamine-based patient-controlled intravenous analgesia on postoperative pain and quality of recovery after video-assisted thoracoscopic lobectomy: A prospective, double-blind, randomized controlled trial.
Trial report in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis double-blinded randomized study aimed to investigate the effects of esketamine-based patient-controlled intravenous analgesia (PCIA) on postoperative analgesia and quality of recovery in patients undergoing video-assisted thoracoscopic (VATS) lobectomy.
methodsPatients undergoing selective VATS lobectomy were enrolled and randomly assigned (1:1) to receive PICA with 1.5 mg/kg esketamine (group K) or 1.5 mg/kg sufentanil (group S). Pain intensity was evaluated using the short-form of the McGill Pain Questionnaire (SF-MPQ) and the visual analog scale (VAS). The primary endpoint was the SF-MPQ score of patients on postoperative day 1.
resultsBetween December 2021 and May 2022, 84 eligible patients received the allocated treatment, with 80 patients (40 per group) ultimately included in the analysis. The total SF-MPQ score in group K was lower than that in group S on postoperative day 1 (P < 0.001) and day 2 (P < 0.001). Additionally, the VAS-rest, VAS-movement and patients' depression-related scores in group K were all significantly lower than those in group S on postoperative day 1 (P = 0.012, P = 0.008 and P = 0.009, respectively) and day 2 (all P < 0.001), whereas the postoperative recovery quality was significantly higher in group K than that in group S on postoperative days 1 and 2 (both P < 0.001). A lower incidence of total adverse events (AEs) was observed in group K than in group S (15% vs. 35%, P = 0.039).
conclusionThe use of 1.5 mg/kg esketamine in PCIA for postoperative analgesia in patients undergoing VATS lobectomy showed a promising analgesic effect and improved perioperative depression and postoperative recovery quality, with no severe AEs observed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.